

NEUREN PHARMACEUTICALS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)



ANNUAL GENERAL MEETING
Tuesday, 22 June, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RE-ELECTION OF PATRICK DAVIES AS A DIRECTOR	NA	34,109,026 99.06%	2,499 0.01%	321,893 0.93%	212,806	34,821,119 99.99%	2,499 0.01%	212,806	Carried
2	AUDITOR FEES AND EXPENSES	NA	34,153,329 98.59%	167,002 0.48%	321,893 0.93%	4,000	34,865,422 99.52%	167,002 0.48%	4,000	Carried
3	APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY UNDER LISTING RULE 7.1A	NA	33,949,238 98.00%	344,943 1.00%	347,143 1.00%	4,900	34,686,581 99.02%	344,943 0.98%	4,900	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item